Report of a Phase I Clinical Trial for Safety Assessment of Human Placental Mesenchymal Stem Cells Therapy in Patients with Critical Limb Ischemia (CLI)

This phase I dose-escalation study investigated placenta-derived MSCs in nine CLI patients who were enrolled into each of the two dosage groups, delivered intramuscularly twice, two months apart.